Involvement of apoptosis inhibitor of macrophages in a rat hypertension model with nephrosclerosis: Possible mechanisms of action of olmesartan and azelnidipine

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 8, 2013, Pages 1271-1277

  Uramatsu, Tadashi ^a,b   Nishino, Tomoya ^a   Obata, Yoko ^a,b   Sato, Yohei ^c   Furusu, Akira ^a   Koji, Takehiko ^d   Miyazaki, Toru ^c   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Apoptosis; Macrophage; Nephrosclerosis; Oxidized low density lipoprotein

Indexed keywords

APOPTOSIS INHIBITOR OF MACROPHAGE; AZELNIDIPINE; DNA NUCLEOTIDYLEXOTRANSFERASE; HYDRALAZINE; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; OXIDIZED LOW DENSITY LIPOPROTEIN; SECRETORY PROTEIN; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; GLOMERULUS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY INTERSTITIUM; MACROPHAGE; MACROPHAGE MIGRATION; MALE; NEPHROSCLEROSIS; NICK END LABELING; NONHUMAN; RAT;

EID: 84883158777     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00965     Document Type: Article

References (42)

1. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet, 365, 331-340 (2005).
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA, 298, 2038-2047 (2007).
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med., 351, 1296-1305 (2004).
4. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int., 68, 228-236 (2005).
5. Nakaya H, Sasamura H, Hayashi M, Saruta T. Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J. Am. Soc. Nephrol., 12, 659-666 (2001).
6. Mimura I, Nangaku M. The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat. Rev. Nephrol., 6, 667-678 (2010).
7. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation, 90, 775-778 (1994).
8. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke, 37, 1923-1932 (2006).
9. Hilgers KF, Hartner A, Porst M, Mai M, Wittmann M, Hugo C, Ganten D, Geiger H, Veelken R, Mann JF. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury. Kidney Int., 58, 2408-2419 (2000).
10. Hartner A, Porst M, Klanke B, Cordasic N, Veelken R, Hilgers KF. Angiotensin II formation in the kidney and nephrosclerosis in Ren-2 hypertensive rats. Nephrol. Dial. Transplant., 21, 1778-1785 (2006).
11. Rodriguez-Iturbe B, Johnson RJ. Role of inflammatory cells in the kidney in the induction and maintenance of hypertension. Nephrol. Dial. Transplant., 21, 260-263 (2006).
12. Imakiire T, Kikuchi Y, Yamada M, Kushiyama T, Higashi K, Hyodo N, Yamamoto K, Oda T, Suzuki S, Miura S. Effects of renin-angiotensin system blockade on macrophage infiltration in patients with hypertensive nephrosclerosis. Hypertens. Res., 30, 635-642 (2007).
13. Miyazaki T, Hirokami Y, Matsuhashi N, Takatsuka H, Naito M. Increased susceptibility of thymocytes to apoptosis in mice lacking AIM, a novel murine macrophage-derived soluble factor belonging to the scavenger receptor cysteine-rich domain superfamily. J. Exp. Med., 189, 413-422 (1999).
14. Arai S, Shelton JM, Chen M, Bradley MN, Castrillo A, Bookout AL, Mak PA, Edwards PA, Mangelsdorf DJ, Tontonoz P, Miyazaki T. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab., 1, 201-213 (2005).
15. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359, 995-1003 (2002).
16. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet, 366, 2026-2033 (2005).
17. Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, Rakugi H, Ogihara T, Horiuchi M. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension, 43, 263-269 (2004).
18. Inaba S, Iwai M, Tomono Y, Senba I, Furuno M, Kanno H, Okayama H, Mogi M, Higaki J, Horiuchi M. Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists. Am. J. Hypertens., 22, 145-150 (2009).
19. Kurashige T, Abe K, Furusu A, Miyazaki M, Obata Y, Xia Z, Nakazawa M, Nakazawa Y, Funakoshi S, Harada T, Koji T, Kohno S. Renoprotective effect of azelnidipine in rats. Biol. Pharm. Bull., 31, 2237-2244 (2008).
20. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn. Circ. J., 27, 282-293 (1963).
21. Oizumi K, Miyamoto M, Koike H. Effects of dihydropyridine Ca blockers on the renal function in nephrotic spontaneously hypertensive rat (SHR). Biol. Pharm. Bull., 17, 407-410 (1994).
22. An S, Hishikawa Y, Liu J, Koji T. Lung injury after ischemiareperfusion of small intestine in rats involves apoptosis of type II alveolar epithelial cells mediated by TNF-alpha and activation of Bid pathway. Apoptosis, 12, 1989-2001 (2007).
23. Koji T, Kondo S, Hishikawa Y, An S, Sato Y. In situ detection of methylated DNA by histo endonuclease-linked detection of methylated DNA sites: a new principle of analysis of DNA methylation. Histochem. Cell Biol., 130, 917-925 (2008).
24. Abo T, Nagayasu T, Hishikawa Y, Tagawa T, Nanashima A, Yamayoshi T, Matsumoto K, An S, Koji T. Expression of keratinocyte growth factor and its receptor in rat tracheal cartilage: possible involvement in wound healing of the damaged cartilage. Acta Histochem. Cytochem., 43, 89-98 (2010).
25. Shirendeb U, Hishikawa Y, Moriyama S, Win N, Thu MM, Mar KS, Khatanbaatar G, Masuzaki H, Koji T. Human papillomavirus infection and its possible correlation with p63 expression in cervical cancer in Japan, Mongolia, and Myanmar. Acta Histochem. Cytochem., 42, 181-190 (2009).
26. Furusu A, Miyazaki M, Abe K, Tsukasaki S, Shioshita K, Sasaki O, Miyazaki K, Ozono Y, Koji T, Harada T, Sakai H, Kohno S. Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis. Kidney Int., 53, 1760-1768 (1998).
27. Yokoyama H, Wada T, Furuichi K. Chemokines in renal fibrosis. Contrib. Nephrol., 139, 66-89 (2003).
28. Sean Eardley K, Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int., 68, 437-455 (2005).
29. Lu H, Kanazawa M, Ishida A, Tufescu A, Sasaki Y, Ito O, Kurosawa H, Sato T, Ootaka T, Kohzuki M. Combination of chronic exercise and antihypertensive therapy enhances renoprotective effects in rats with renal ablation. Am. J. Hypertens., 22, 1101-1106 (2009).
30. Rodríguez-Iturbe B, Pons H, Herrera-Acosta J, Johnson RJ. Role of immunocompetent cells in nonimmune renal diseases. Kidney Int., 59, 1626-1640 (2001).
31. Naya M, Tsukamoto T, Morita K, Katoh C, Furumoto T, Fujii S, Tamaki N, Tsutsui H. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J. Am. Coll. Cardiol., 50, 1144-1149 (2007).
32. Fan YY, Kohno M, Nakano D, Hitomi H, Nagai Y, Fujisawa Y, Lu XM, Fu H, Du J, Ohmori K, Hosomi N, Kimura S, Kiyomoto H, Nishiyama A. Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats. J. Hypertens., 27, 1855-1862 (2009).
33. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J. Am. Soc. Nephrol., 16, 3631-3641 (2005).
34. Kadowaki D, Anraku M, Tasaki Y, Taguchi K, Shimoishi K, Seo H, Hirata S, Maruyama T, Otagiri M. Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats. Biol. Pharm. Bull., 32, 2041-2045 (2009).
35. Konno S, Hirooka Y, Araki S, Koga Y, Kishi T, Sunagawa K. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. J. Cardiovasc. Pharmacol., 52, 555-560 (2008).
36. Manabe S, Okura T, Fukuoka T, Higaki J. Antioxidative effects of azelnidipine on mesangial cell proliferation induced by highly concentrated insulin. Eur. J. Pharmacol., 567, 252-257 (2007).
37. Matsui T, Yamagishi S, Nakamura K, Kikuchi S, Inoue H. Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells. Drugs Exp. Clin. Res., 31, 215-219 (2005).
38. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J. Am. Soc. Nephrol., 13, 2478-2487 (2002).
39. Naito Y, Shimozawa M, Manabe H, Nakabe N, Katada K, Kokura S, Yoshida N, Ichikawa H, Kon T, Yoshikawa T. Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species. Eur. J. Pharmacol., 546, 11-18 (2006).
40. Tanifuji C, Suzuki Y, Geot WM, Horikoshi S, Takahashi H, Tomino Y. Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys. Kidney Blood Press. Res., 32, 239-249 (2009).
41. Umemoto S, Tanaka M, Kawahara S, Kubo M, Umeji K, Hashimoto R, Matsuzaki M. Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. Hypertens. Res., 27, 877-885 (2004).
42. Fujimoto S, Satoh M, Horike H, Hatta H, Haruna Y, Kobayashi S, Namikoshi T, Arakawa S, Tomita N, Kashihara N. Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production. Hypertens. Res., 31, 305-313 (2008).